A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Exclusion Criteria

• •1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
• •2. Diagnosis of type 1 or type 2 diabetes mellitus or secondary forms of diabetes at Screening
• •3. History of myocardial infarction, unstable angina, arterial revascularization, mechanical prosthetic heart valve, stroke, New York Association Functional Class II-IV heart failure, or transient ischemic attack within 6 months of Screening
• •4. Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin)
• •5. Personal or family history of MTC or MEN2, or study participants with suspected MTC per the investigator's judgment
• •6. Acute pancreatitis, a history of repeated episodes of acute pancreatitis, or history of chronic pancreatitis
• •7. Symptomatic gallbladder disease
• •8. Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders
• •9. History of depressive disorder or history of other severe psychiatric disorders within the last 2 years from Screening
• •10. Any lifetime history of a suicide attempt
• •11. Known medical history of active liver disease, or prior known drug-induced liver injury
• •12. History of HIV infection
• •13. Recent history of bleeding, or risks of bleeding, or abnormal coagulation test (INR \>1.3) result at Screening
• •14. Use of prohibited medications
• •15. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest
• •16. Standard 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study result
• •17. Participants with clinical laboratory test abnormalities at Screening